Department of Psychological Science, University of Texas Rio Grande Valley, Edinburg, TX, USA To delineate score differences between the Wechsler Adult Intelligence Scale-IV (WAIS-IV) and the WAIS-IV ...

Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...

Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus ...

Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line ...

Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues ...

Sage Therapeutics said its Phase 2 trial of dalzanemdor in patients with mild cognitive impairment or mild dementia due to ...

The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.

Emotion Regulation Skills,Game Development,Game Objects,Game Of Chess,Game Training,Head-mounted Display,Humeral Head,Job Performance,Notable Changes,Null Hypothesis,Pseudocode Of ...